Over the last years, a new generation of human immunodeficiency virus (HIV) neutralizing antibodies
was identified. These antibodies are highly potent and are able to
effectively neutralize a large number of different HIV strains.
Therefore, they play an important role in the quest for and development
of an HIV vaccine.
A research team led by investigators of the Rockefeller University in
New York and Prof Florian Klein, University Hospital Cologne and German
Center for Infection Research (DZIF), has tested a new HIV neutralizing
antibody, called 10-1074, in humans. The results of the trial have just
been published in Nature Medicine
‘A new human immunodeficiency virus (HIV) neutralizing antibody, called 10-1074, when tested in humans was well tolerated and demonstrated favorable pharmacokinetic properties.’
collaboration with the Division of Infectious Diseases at the University
Hospital Cologne (Prof Gerd Fätkenheuer) and scientists of the
Rockefeller University in New York, Prof Klein's research group is
investigating whether broadly neutralizing antibodies can be used to
treat HIV infection.
The just published trial investigates this approach. The broadly
neutralizing antibody 10-1074 targets a specific structure (V3 loop) on
the HIV envelope protein. In the study, the investigators show that the
antibody was well tolerated and demonstrated favorable pharmacokinetic
Additionally, the antibody showed high antiviral activity in
the participants with HIV infection. Furthermore, the team was able to
specifically investigate the development of resistant HIV variants.
performed a comprehensive HIV sequence analysis to investigate the
dynamics and mechanisms HIV uses to escape the selection pressure by the
antibody," says Dr. Henning Gruell, one of the first authors of the
"This trial was only possible because of the intensive collaboration
with the Rockefeller University and many other clinical and scientific
partners," says Prof Klein, principal investigator in Germany and
co-last author of the study. The scientists are planning further trials
to investigate an antibody-mediated treatment approach in patients with
HIV infection. Further trials have already been scheduled for spring.